12:00 AM
Mar 29, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Remune: Phase III trial update

The Immune Response Corp. (IMNR), Carlsbad, Calif.
Product: Remune
Business: Infectious diseases
Therapeutic category: Immune stimulation
Target: HIV core proteins
Description: Inactivated gp120-depleted HIV-1...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >